The private British biotech announced positive results from its Phase IIa study of BPL-003, which it said support its Phase IIb study of the same DMT-based drug.

In this second roundup from CES, Medtech Insight shines the light on Proto Hologram’s many use cases in health care, Intuition Robotics’ ElliQ robot to help the elderly feel less lonely, MIT AgeLab’s Aging Suit, Siemens/Unlimited Tomorrow’s partnership on a bionic prosthetic arm, and Earable Neuroscience’s Frenz Brainband to promote better sleep.

In Vivo talks to investors, analysts and companies in rare disease about the challenges they face to innovate and to grow.

CymaBay and Genfit have been positioning their failed NASH candidates, both PPAR agonists, for approval in second-line primary biliary cholangitis. Analysts call both approvable, but say CymaBay’s drug has a better overall profile.